EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq:LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests, announced today that it has submitted a request to the U.S. Food and Drug Administration for emergency use authorization (EUA) for its COVID-19 & Flu test. The request is for prescription at-home use of the PCR-quality test for those with suspected COVID-19 or Influenza. Lucira is seeking FDA authorization before this upcoming fall and winter, when SARS-CoV-2 and influenza viruses are likely to co-circulate.
Lucira Files for Authorization of First-of-its-Kind COVID-19 & Flu At-Home Molecular Test
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Broadcom%20Inc%20HQ%20photo-by%20Sundry%20Photogrpahy%20via%20iStock.jpg)
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
